Lilly widens special-access applications for unapproved obesity drug
The expansion opens an application route to more patients before the medicine has cleared regulatory review.
MH
By Maren Holt · Senior Reporter, GLP-1
Aug 3 03:00 ETSource: STAT
The wire
- 01Eli Lilly will allow more patients to apply for special access to an obesity drug that is not yet approved, STAT reported.
- 02Expanded access programs are one of the few legitimate routes to pre-approval incretin therapy and will draw questions from clinicians fielding patient requests.
- 03Eligibility criteria, volumes and cost to patients were not detailed, and access remains at the company's discretion.
From the source
Read at statnews.comEli Lilly to allow more patients to apply for special access to unapproved obesity drug